{"name":"Apimeds, Inc.","slug":"apimeds-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":98544,"netIncome":-1389990,"cash":3455,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Apitox - pure honeybee toxin","genericName":"Apitox - pure honeybee toxin","slug":"apitox-pure-honeybee-toxin","indication":"Rheumatoid arthritis","status":"phase_3"}]}],"pipeline":[{"name":"Apitox - pure honeybee toxin","genericName":"Apitox - pure honeybee toxin","slug":"apitox-pure-honeybee-toxin","phase":"phase_3","mechanism":"Apitoxin, the active component of honeybee venom, exerts anti-inflammatory and immunomodulatory effects through phospholipase A2 and other peptide components that modulate immune cell activity and reduce inflammatory mediators.","indications":["Rheumatoid arthritis","Inflammatory joint disorders"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9pSmtwVWNtVGVidnJ3emhtRVFId2tHN2dSSUlNWno4STZKb3pqVko4M0c0NFFNN0ZjSzhKRGdHLXdnVjdsNUw5WnNpRmxSVEc3SWJwcWNvVE9tOFZ0S3ZV?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"APUS Stock Price, Quote & Chart | APIMEDS PHARMACEUTICALS US I (NYSEARCA:APUS) - ChartMill","headline":"APUS Stock Price, Quote & Chart | APIMEDS PHARMACEUTICALS US I (NYSEARCA:APUS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM3NXaWlWakdza3VoUjRXSnZ0TV9nN3A0ZGFIWmFDX0FRNXNJbC1XVElFeGN4dGp1OVZBZVJuODVqMFBBTkZHRV8xV1VLckdFeTRZb2RTc241ak9aSnhOSjlDdzV4dTI5dXpZMGEwU3hJSjVVSHpnN2ZRY2w2Y2pkWDhZWE85eXdoOEN0NjVPYTRGc0h3U3Z3TUliQ19ULS1OSk1Z?oc=5","date":"2026-04-01","type":"pipeline","source":"TipRanks","summary":"Apimeds Pharmaceuticals Delays Annual 10-K Filing - TipRanks","headline":"Apimeds Pharmaceuticals Delays Annual 10-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNYWliMGlVQWFfQmtNRTAzazdTVVhGY3VMMndoVWJxbWlDMnR2UlhHRW5PbVUxMlRaYWhHLVdET3BlYW5Wa2NlVVZ2dVd2SUh1ZGtOZ0k1SWFxdXBLc25UN1hPdGF1UU00UUJNTkJab1VOamtJdDk0Q0hwM1pxV0FRVXJKU3pxQTZlem9WZTNvR0hmbzZNaWhFWFo5WEdOUU5ROWRxMUwzblA5LTUzV2NrRHFhTGg1NUQwZzJqeUVNdmNOVkktS0lRRVVwRQ?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"[SCHEDULE 13D/A] Apimeds Pharmaceuticals US, Inc. Amended Major Shareholder Report - Stock Titan","headline":"[SCHEDULE 13D/A] Apimeds Pharmaceuticals US, Inc. Amended Major Shareholder Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNRVlwakdyYzd3Y3d3Wl9IWlBJR3NmV016cUxzak4xUTZnSlhhUTItTUFFdDZIWTJPcUhmRFR1eEVEQVpPRXRtSGpTYXVlQjRWVEdOWnFNLTV5VTFHazRGaGlsSGJBMmp4MDlOQk5NeU1UMlhEV0RFTGxmX0lYa2laUzNlWjhremVITGEyUUVCaEhzUjEyZnh3blNHWWxsdUtvZkZmSmg2RVlHLXNHSzRjc3l3TWk2YVV2QjRpUQ?oc=5","date":"2026-03-26","type":"pipeline","source":"TipRanks","summary":"Apimeds Pharmaceuticals US Challenges Disputed Boardroom Power Shift - TipRanks","headline":"Apimeds Pharmaceuticals US Challenges Disputed Boardroom Power Shift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOR2FOd05POGMzS3RJaDB2LXV5OHFxczlZSFNhUlFZNExaSTU0b2RlcE9Vbno2Rkh2WHUwaWttT04teGJOTUQ0ZnJ0RDlZTUtEWmpORl96a2MyZThTVTVUdlhIeUZYbmNpaFI0bjVMaE1JZTlwUmhESlpFSVpual9LelgzT3B0cGdneUhMRTdXdlVYT3BteE9vWl9XUTI0cHhpbklFVHUzTGZhNmlUamZwam44MlBCX05E?oc=5","date":"2026-03-26","type":"pipeline","source":"marketscreener.com","summary":"Apimeds Pharmaceuticals Us, Inc. Announces Update on Board Changes - marketscreener.com","headline":"Apimeds Pharmaceuticals Us, Inc. Announces Update on Board Changes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPVUNXTndUMGVzNVZnSXJ6YnViRS1IamVFNHlTOTA5a2JIcV9CNmdxVE5ucDJCTEItOWdRZlRHd3N2V0RwVnQxTTJVbHVWN3dNcGZKZUpZYmxxTzRLX2xXLU1xQmhRc0UyS1lrTWdwYXFkM3FtMUoya3AxYkFQclF1ejlEMnAwR09walk0Z0h6NFFLcTJ5bEF6V2VrYjZMdEpDTDEtb0dVRGtvNk03RlVLQ1JKSGN3dw?oc=5","date":"2026-03-26","type":"pipeline","source":"marketscreener.com","summary":"Apimeds Pharmaceuticals Us, Inc. Announces Update on CEO Changes - marketscreener.com","headline":"Apimeds Pharmaceuticals Us, Inc. Announces Update on CEO Changes","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbzVkRFg2Ni1hQUVQSzFLOXRTX25fYkNWZjlyOElUNENVRGx3TXh6QzlOYVRuLXdMYUVMNXQ0eV9OQk5OM3hJdXo5LWg0Qm1uTlNUYjU4ZUdEVDJEWVdMOUg3dmswUWJzSUhNZkFZTk41LW9mcGk3ZklVN1RzQTkyUzl2d200Q2V3YW81c21TbkZEbUdsRjNtczdKc3B3QjZvU0VtaDExWTRDX1EwOTM3ZlpEM2JjX1VLOUs4?oc=5","date":"2026-03-25","type":"pipeline","source":"Stock Titan","summary":"[8-K] Apimeds Pharmaceuticals US, Inc. Reports Material Event - Stock Titan","headline":"[8-K] Apimeds Pharmaceuticals US, Inc. Reports Material Event","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNRTlkZWtNdUI1NnJGaFQxZm5YTFJmTS1ieG9aSnVIamVwRElVSjQyOUFxalpMRXhYbWY0MnU3TGFTVXdVay1KZ1gzRTIwWDNsTDBUazV0Q0xSUE9hV0xlWFRSMlM1dkk3UGhzVWp6c2xYYllNNjBMTmY1TndvQkFKa3NXcjFmdHJ4WWJHRHpQRkI4Njh1UzRqTzd1NEhSbC10WFF1U2RLUnExWVdWVUpoM00zN2xZM0RKWTlWM2tn?oc=5","date":"2026-03-25","type":"pipeline","source":"Stock Titan","summary":"Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc. - Stock Titan","headline":"Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPbERtcWRPbGdhNVZEZF9sUXZkbkczek16SV84NURuRUdsMFVfcGpVUEVsaVpRMHVuOHhfZVJQTnU4elYtdUZfbHNJY1FzcWVFdFh0TDNUZDRqSUpZUUxzcm04SmJ0TlNNOWZZNnFpblJOT3hkUnlITmJJdmZIeVB4Zk80NGNkbzlUY044QWR3WURfc2VqNTBpOUFkMmNZeGJ0bXdrcUtVby1SNU5FNmV3bE1NaFFycFppNkNMUlpZNm9VUmpUYkFyUDVLSVptZ09ERTJnbGlibUZEY0RxTW5KdExMbmpWYkU?oc=5","date":"2026-03-24","type":"deal","source":"marketscreener.com","summary":"Apimeds Pharmaceuticals US Inc. announces material breach of merger agreement by Inscobee Inc and Apimeds Inc - marketscreener.com","headline":"Apimeds Pharmaceuticals US Inc. announces material breach of merger agreement by Inscobee Inc and Apimeds Inc","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPSjVWSGdzTTZaY29wbjR1c3NlUWtPUllTM2xsV0NITHpMaGRtbzZYNUhnVUkxazRTUlBUc0dweUo0NXVaa01XbTNIVWlXWEpad1RMbzFTY1M5TWZqNHdIa0tHMTlaNW5hZmJqMUlyUzRRdkdBYncwR1BxRmFabVl1SjZGN1FqbzFid3l6ZkQ5QWUzNGY3WTdSVVAxTDFmend4Z0p1ckZad0FnNWp0cV9JOEdPeU4?oc=5","date":"2025-12-10","type":"pipeline","source":"Investing.com","summary":"Apimeds Pharmaceuticals closes $100 million PIPE financing - Investing.com","headline":"Apimeds Pharmaceuticals closes $100 million PIPE financing","sentiment":"neutral"},{"date":"2025-12-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":98544,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1389990,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":3455,"cashHistory":[],"totalAssets":13057,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}